Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Woodcock: FDA Focused On Biosimilars Science Before Policy

This article was originally published in Scrip

Executive Summary

Under fire from lawmakers, Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, took cover by insisting the reason the agency has yet to issue or finalize some of the most important biosimilars guidance documents industry has been waiting on – specifically, those on interchangeability and labeling – is because regulators must first "get the science right."

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register